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E-mail address: apfelc@anesthesia.ucsf.edu (C.C. AOpioids are a key risk factor for postoperative nausea and vomiting (PONV). As intravenous (i.v.) acetami-
nophen reduces postoperative pain and opioid requirements, one would expect i.v. acetaminophen to be
associated with a lower incidence of opioid-induced side effects, including PONV. We conducted a sys-
tematic search using Medline and Cochrane databases supplemented with hand search of abstract pro-
ceedings to identify randomized-controlled trials of i.v. acetaminophen. Inclusion criteria were (a)
randomized for i.v. acetaminophen vs a placebo control, (b) general anesthesia, and (c) reported or
obtainable PONV outcomes. Primary outcome was postoperative nausea and secondary outcome was
postoperative vomiting. We included 30 studies with 2364 patients (1223 in the acetaminophen group,
1141 in the placebo group). The relative risk (95% conﬁdence interval) was 0.73 (0.60–0.88) for nausea
and 0.63 (0.45–0.88) for vomiting. Data showed signiﬁcant heterogeneity for both nausea (P = 0.02,
I2 = 38%) and vomiting (P = 0.006, I2 = 47%), but were homogeneous when studies were grouped according
to timing of ﬁrst administration: i.v. acetaminophen reduced nausea when given prophylactically either
before surgery, 0.54 (0.40–0.74), or before arrival in the postanesthesia care unit, 0.67 (0.55–0.83); but
not when given after the onset of pain, 1.12 (0.85–1.48). When i.v. acetaminophen was given prophylac-
tically, the reduction of nausea correlated with the reduction of pain (odds ratio 0.66, 0.47–0.93), but not
with reduction in postoperative opioids (odds ratio 0.89, 0.64–1.22). Prophylactically administered i.v.
acetaminophen reduced PONV, mainly mediated through superior pain control.
 2013 International Association for the Study of Pain. Published by Elsevier B.V.Open access under CC BY-NC-ND license. 1. Introduction
Postoperative nausea and vomiting (PONV) occurs in about 30%
of all patients undergoing general anesthesia, and the main triggers
are known to be inhalational anesthetics and opioids [2,3,27,51].
While the emetogenic inhalational anesthetics may be substituted
with intravenous (i.v.) propofol infusions, it is more difﬁcult to re-
place or at least minimize the use of opioids [2,50]. However, even
if itmaynot be generally possible to eliminate opioids, the reduction
of opioid consumption is generally thought to be associated with
fewer opioid-related side effects. For example, systematic reviews
and meta-analyses of the use of nonsteroidal anti-inﬂammatoryPain. Published by Elsevier B.V.
idemiology and Biostatistics,
47, San Francisco, CA 94115,
pfel).
Odrugs (NSAIDs) and pregabalin as part ofmultimodal analgesia have
demonstrated a reduction in PONV by about 30%, which is compara-
ble to the efﬁcacy known from conventional antiemetics [29,54].
While oral and rectal acetaminophen has been on the market
for many decades, i.v. acetaminophen was introduced only about
10 years ago in Europe and 2 years ago in the United States. The
key advantage of i.v. acetaminophen seems to be that 1 g of i.v.
acetaminophen is associated with about twice the plasma and ef-
fect site concentrations as 1 g of its oral or rectal applications,
resulting in greater central nervous system penetration [44], which
corroborates the superior analgesic efﬁcacy seen with i.v. com-
pared to oral acetaminophen in the surgical setting [38].
According to systematic reviews and meta-analyses, acetamino-
phen has also been shown to reduce opioid requirements [32,47].
However, to our surprise, this did not translate to a reduced inci-
dence of PONV. A closer look revealed that those reviews focused
on studies with pain or opioid consumption as the primary endpen access under CC BY-NC-ND license. 
178 records identified through PubMed,  
62 records identified through Cochrane 
10 additional records identified 
through other sources
217 records after 33 duplicates removed
217 abstracts screened 143 records excluded
74 full-text articles 
assessed for eligibility
30 studies included in 
qualitative and 
quantitative synthesis 
(meta-analysis)
44 full-text articles excluded 
(multiple reasons possible):
Not randomized for IV 
acetaminophen, n=15
No inactive control, n=20
No general anesthesia, n=12
No PONV data, n=4
Fig. 1. Flow chart of systematic identiﬁcation, screening, and eligibility assessment
of studies. IV, intravenous; PONV, postoperative nausea and vomiting.
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in the last 2 years, a number of new studies have been published
reviewing PONV and acetaminophen [15,30].
Thus, our objective was to systematically review the effect of i.v.
acetaminophen on nausea and vomiting in randomized controlled
trials in patients who received general anesthesia.
2. Material and methods
According to a prospectively drafted protocol, we searched
Medline using the search string ‘‘(acetaminophen OR paracetamol)
AND (PONV)’’ using the limits ‘‘(human AND clinical trial AND ran-
domized controlled trial)’’ on March 4, 2012. Eligible studies were
abstracts or full papers with no language restrictions, but all stud-
ies had to be randomized, placebo-controlled, and report the inci-
dences or number of patients with nausea, vomiting, or both.
Nausea and vomiting are 2 distinct phenomena and, as we have
pointed out before, the study of PONV should assess and report
these variables separately [4]. But because few patients experience
vomiting without nausea, the incidence of postoperative nausea
(PON) and PONV is generally fairly similar and thus, original papers
often do not distinguish between these variables [50]. Thus, when
both PON and PONV were reported, we used the nausea values, and
if PONV but not PON was reported, we considered the PONV vari-
ables as a very close surrogate for PON. The most commonly re-
ported time interval to measure the efﬁcacy of antiemetics is 24
hours [4]. If another shorter or longer time interval was reported,
we used the time interval that was closest relative to the 24-hour
interval. If data were unclear or missing, we contacted the authors
to ask for additional information.
Included studies had to report PON, PONV, or postoperative
vomiting, either as a primary end point, secondary end point, or
as adverse events. Our primary hypothesis was that i.v. acetamino-
phen will reduce PON, possibly through reduction in postoperative
opioid requirements. In addition, we expected the effect size for
vomiting to be similar; acknowledging that due to the much lower
incidence of vomiting compared to nausea, there could be insufﬁ-
cient power for a statistically signiﬁcant effect even though the ef-
fect size could be similar to that for nausea. Furthermore, we
planned sensitivity analyses for the source of funding, dosage,
and meta-regressions to study the effects of postoperative opioid
and pain reduction. Because we found that i.v. acetaminophen
did not reduce PONV when it was dosed many hours and often
the following days after surgery as a rescue medication, we con-
ducted sensitivity analyses on patients in whom i.v. acetamino-
phen was given prophylactically. We analyzed all reported
outcomes for potential publication bias by examining funnel plots
and performing Egger’s regression tests [16].
This study was conducted in accordance with the Preferred
Reporting Items for Systematic reviews and Meta-Analysis (PRIS-
MA) statement [35]. Analyses were primarily conducted with Rev-
Man 5.1 (Cochrane Collaboration, Copenhagen, Denmark), and we
calculated the relative risk of the events for the intervention versus
the placebo control group using the more conservative random-ef-
fects model. We also calculated the number needed to treat; how-
ever, this measure needs to be cautiously interpreted since
numbers needed to treat for prophylactic interventions are highly
dependent on baseline incidences and thus should not be used to
compare interventions among trials with different baseline inci-
dence [8]. For meta-regressions and Egger’s regression tests, we
used Comprehensive Meta-Analysis 2.2 (Biostat; Englewood, NJ,
USA) and conﬁrmed the results with STATA 9.0 (StataCorp LP, Col-
lege Station, TX, USA). Postoperative opioid consumption was con-
verted to morphine equivalents and the regression was conducted
on 10-mg morphine equivalents to make the coefﬁcient morecomparable to other factors. Reporting of postoperative pain was
rather heterogeneous, and conversions were performed as neces-
sary. First, we converted pain values to an 11-point pain scale
(0–10). Second, we calculated the area under the pain curve for
each group and divided the between-group differences by the
duration of observation (usually 24 hours), which resulted in an
average pain intensity difference.
3. Results
3.1. Search
Search using Medline and Cochrane databases revealed 178 and
62 hits, respectively, with 33 duplicates (Fig. 1). Hand search of ref-
erences and contacting Cadence Pharmaceuticals, Inc (San Diego,
CA) revealed 10 additional references, leading to a total of 217 ref-
erences. After reviewing the title and abstracts, 143 references
were excluded because they did not meet the inclusion criteria
(eg, treatment of acetaminophen overdose) and 74 full-text articles
were assessed for ﬁnal eligibility. Of those, a further 44 articles
were excluded for the following reasons (note that one study could
have more than one reason): not randomized for i.v. acetamino-
phen (n = 15), no inactive control (n = 20), patients did not receive
surgery under general anesthesia (n = 12), and PONV data were
missing and not obtainable (n = 4). Thus, we identiﬁed 30 papers
(with 32 comparisons) with 2364 patients (1223 in the acetamino-
phen group, 1141 in the placebo group; Table 1 [5–7,9–11,13,17–
23,25,26,28,33,34,36,37,39,42,43,45,46,48,49,52]).
3.2. Efﬁcacy data
Intravenous acetaminophen was associated with a relative risk
(95% conﬁdence interval) of 0.73 (0.60–0.88) for nausea (Fig. 2) and
0.63 (0.45–0.88) for vomiting (Fig. 3), but with signiﬁcant hetero-
geneity for both nausea (P = 0.02) and vomiting (P = 0.006; Table 2).
Number needed to treat for i.v. acetaminophen was 12.3 (7.6–32.3)
for nausea and 14.2 (8.3–50.8) for vomiting. Sensitivity analysis re-
vealed that i.v. acetaminophen reduced nausea (0.63, 0.54–0.75)
and vomiting (0.42, 0.31–0.56) in investigator-initiated trials, but
did not reduce nausea (1.12, 0.85–1.48) and even increased vomit-
ing (1.41, 1.02–1.96) in industry-sponsored clinical trials. A closer
look showed that i.v. acetaminophen was generally started pro-
phylactically in investigator-initiated trials, while it was generally
Table 1
Characteristics of included studies.
Study (ﬁrst
author) Year
Number of
patients
acetaminophen
Number
of
patients
placebo
Risk of bias
assessmenta
Patients/type of
surgery
Intervention Outcomes Comments
Arici [5]
2009
55 27 U/U/H/H/U ASA I-II, elective
abdominal
hysterectomy
1 g i.v. paracetamol before
surgery 1 g i.v. paracetamol
(prior to skin closure)
Morphine consumption 1, 2,
4, 8, 12, 24 h
Pain VAS (0–10) score 1, 2, 4,
8, 12, 24 h
Nausea, vomiting, itching,
SpO2 0–24 h
Hospital stay
Arslan [6]
2011
20 20 L/H/L/L/L ASA I-II, elective
thyroidectomy
1 g i.v. acetaminophen
intraoperatively 8 mg
lornoxicam intraoperatively
Pain VAS 0.25, 1, 2, 4, 6, 8,
12, 18, 24
Time to ﬁrst analgesic
(tramadol)
Patient satisfaction
Nausea, vomiting 0–24 h
Allergy, hypotension 0–24 h
Atef [7]
2008
38 38 L/L/L/L/L Elective tonsillectomy 1 g i.v. paracetamol
immediately after end of
surgery and for every 6 h for
18 h
Pain VAS 1, 2, 3, 4, 24 h
Number of pethidine doses
Nausea and vomiting 0–24 h
Headache 0–24 h
Brodner [9]
2010
49 49 L/L/L/L/L ASA I-III, minor-to-
intermediate surgery
1 g i.v. acetaminophen every
6 h intraoperatively 1 g
dipyrone every 6 h
intraoperatively 40 mg
parecoxib every 12 h
intraoperatively
Pain VAS 1,6, 18, 30, 42 h
Time to ﬁrst piritramide
Piritramide consumption
Patient satisfaction
Respiratory depression
Nausea and vomiting
Sedation, sweating
Cakan [10]
2008
20 20 L/L/H/L/L ASA I-III, elective
lumbar laminectomy
and diskectomy
1 g i.v. acetaminophen at
end of surgery and for every
6 h for 24 h
Pain VAS 1, 2, 4, 6, 12, 18,
24 h
Patient satisfaction
Nausea and vomiting 0–24 h
Sedation 0–24 h
Dizziness, headache,
drowsiness, hypotension 0–
24 h
Candiotti
[11] 2008
166 165 L/L/L/L/U ASA I-III, lower
abdominal, non-
laparoscopic,
gynecological surgery
1 g i.v. acetaminophen after
surgery and for every 6 h for
48 h
Sum of pain intensity at 24
and 48 h
Pain relief Time to ﬁrst
rescue morphine
Total morphine
consumption after 24 and
48 h
Patients’ satisfaction
Cattabriga
[13] 2007
56 57 L/L/L/L/L Elective cardiac
surgery
1 g i.v. acetaminophen at
end of surgery
And for every 6 h for 72 h
Pain VAS 12, 18, 24, 30, 36,
42, 48, 54, 60, 66, 72 h
Morphine consumption 0–
72 h
Nausea and vomiting
Cardiorespiratory
parameters
Cok [15]
2011
41 45 L/L/L/L/L ASA I-II, strabismus
surgery in children 2–
14 years
15 mg kg1 i.v. paracetamol Faces pain scale 0–24 h
Number of analgesic
interventions
Nausea and vomiting 0–24,
24-48 h
All patients
received
dexamethasone
0.1 mg kg1
10 mg kg1
paracetamol as
analgesic rescue
medication
Emir [17]
2010
30 30 L/H/H/H/U Elective spinal
vertebral surgery
1 g i.v.
paracetamol + 0.75 mg kg1
tramadol immediately after
surgery
1.5 mg kg1 tramadol
immediately after surgery
0, 0.25, 0.5, 1, 2, 4, 6, 12, 18,
24 h
Numeric rating scale for pain
assessment 4-point nausea
scale
Cardiorespiratory
parameters
Average was
taken Group T:
17/7 = 2.43
Group P: 4/
3 = 1.33
Fadly [18]
2006
10 10 U/U/H/H/U ASA I-II, surgical
release of post burn
neck contractures
1 g
paracetamol + 0.05 mg kg1
morphine 1 g paracetamol
Study drug given
immediately after
extubation
Pain score 0, 0.25, 0.5, 0.75 1,
2, 4, 6 h
Time to ﬁrst morphine
rescue dose
Total morphine
consumption
Patient satisfaction
Nausea or vomiting 0–6 h
Additional
morphine
0.05 mg kg1
(continued on next page)
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Table 1 (continued)
Study (ﬁrst
author) Year
Number of
patients
acetaminophen
Number
of
patients
placebo
Risk of bias
assessmenta
Patients/type of
surgery
Intervention Outcomes Comments
Sedation SpO2
Gimbel [19]
2008
30 31 L/L/L/L/L Elective hip
arthroplasty
1 g i.v. acetaminophen ﬁrst
morning after surgery and
repeated after 4, 10, 16 h
First dose: Pain intensity
difference 0.25, 0.5, 0.75, 1,
2, 3, 4 h post dose
Pain intensity and pain relief
derived scores
PAR, SPID, TOTPAR, MAXPID,
MAXPAR
Rescue, frequency,
administration, amount
Repeated doses: PID at 1, 5,
11, and 17 h
Nausea
Gokten [20]
2011
20 20 U/H/H/L/L Percutaneous
nephrolithotomy
1 g i.v. paracetamol
postoperatively and
repeated
4/day 20 mL 0.25%
levobupivacaine + 1 g i.v.
paracetamol
postoperatively repeated 4/
day 20 mL 0.25%
levobupivacaine
Pain VAS at 6 and 24 h
Percentage meperidine
rescue medication
Side effects: Nausea or
vomiting
Sedation, respiratory
depression, hypotension,
pruritus, dizziness, sweating,
dry mouth
Additional 0.25%
levobupivacaine
inﬁltration
Grundmann
[21] 2006
20 20 L/L/L/L/L ASA I-II, unilateral
microsurgical lumbar
diskectomy
1 g i.v. paracetamol
40 mg parecoxib
1 g metamizol
Before the end of surgery
All outcomes for ﬁrst 2 h
postsurgery
Pain VAS
Patients requiring additional
pain therapy
Time to rescue piritramide
Cumulative piritramide dose
Nausea and vomiting
Shivering, pruritus, mean
arterial pressure, heart rate
Hong 1 [23]
2010
31 32 L/L/L/L/L Children 6-24 months,
elective
ureteroneocystostomy
15 mg kg1 iv
acetaminophen + 0.5
lg kg1 intraoperatively
0.5 lg kg1 intraoperatively
Parent nurse-controlled
analgesia with i.v.
acetaminophen in
treatment group
Postoperative fentanyl dose
at 1,6, 12, 24, 36, 48, 60, 72 h
Children’s Hospital of
Eastern Ontario Pain Scale at
1,6, 12, 24, 36, 48, 60, 72 h
Parent satisfaction
Side effects (0–72 h):
Vomiting, sedation, pruritus,
poor oral feeding,
desaturation
Additional
fentanyl
0.5 mg kg1
Hong 2 [22]
2010
63 61 L/U/L/L/L ASA I-II, women,
robot-assisted
endoscopic total
thyroidectomy
1 g i.v. paracetamol before
induction of anesthesia and
for every 6 h for 24 h
Pain VAS at 1, 3, 6, 12, 24, 48,
72 h
Time to rescue fentanyl
Side effects: Nausea and
vomiting
Drain output
Jokela [25]
2010
40 40 L/L/L/L/L ASA I-III, laparoscopic
hysterectomy
1 g acetaminophen at
induction of anesthesia and
for every 6 h for 24 h
1 g acetaminophen at
induction of anesthesia and
for every 6 h for 24 h + 4 mg
ondansetron
NRS pain scale at 1, 2, 4, 6, 8,
18, 24 h
Time to ﬁrst rescue
oxycodone
Total oxycodone dose 0–24 h
Patient satisfaction
Side effects (0–24 h): PONV,
vomiting, dizziness,
headache, lack of
concentration, pruritus
Kiliçaslan
[26] 2010
25 25 L/L/L/L/L ASA I-II, cesarean
section
1 g paracetamol before end
of surgery and for every 6 h
for 24 h
Patient-controlled tramadol
analgesia
Pain (VAS) 1, 3, 6, 12, 24 h
postoperative
Sedation score (5-point) 1, 3,
6, 12, 24 h postoperative
PCA demand and delivery
ﬁrst 24 h
Total tramadol consumption
ﬁrst 24 h
Side effects (0–24 h):
Nausea, vomiting, use of
antiemetics, dry mouth,
dizziness-drowsiness
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Table 1 (continued)
Study (ﬁrst
author) Year
Number of
patients
acetaminophen
Number
of
patients
placebo
Risk of bias
assessmenta
Patients/type of
surgery
Intervention Outcomes Comments
Lee [28]
2010
20 20 U/U/H/L/L ASA I-II,
thyroidectomy
1 g i.v. paracetamol
700 mg i.v.
paracetamol + 3 mg i.v.
morphine
30 mg i.v. Ketorolac
30 min before end of
surgery
VAS pain score 0.5, 1, 2, 4,
6 h postoperative
Incidence of rescue
pethidine
Patient satisfaction
Side effects (0–6 h): Nausea,
vomiting, headache,
sedation, dizziness,
respiratory depression
Memis [33]
2010
20 20 L/L/H/H/L ASA II-III, major
surgery, ICU patients
1 g i.v. paracetamol + i.v.
meperidine i.v. meperidine
every 6 h for 24 h after
arrival in ICU
Behavioral pain scale (10-
point scale) until extubation
VAS 10-point pain scale after
extubation at 24 h
Sedation score at extubation
Sedation score at 24 h
Adverse effects: respiratory
depression, reintubation,
nausea and vomiting,
treatment for nausea and
vomiting, pruritus
Minkowitz
[34] 2008
23 21 L/L/L/L/U ASA I-III, vaginal
hysterectomy
1 g acetaminophen on
morning of postsurgery day
1 and after 4, 10, 16 h
Pain relief and pain intensity
difference (4-point) at
0,1,2,3, 4 h
Time to maximum pain
relief, maximum pain relief
SPID4, TOTPAR4
Nausea and vomiting, liver
enzymes
Early study
termination due
to particulates in
placebo vials
Moon [36]
2011
36 35 L/L/L/L/H ASA I-II, abdominal
hysterectomy
2 g acetaminophen 30min
before induction of
anesthesia
Total patient controlled
hydromorphone
consumption 0-24 h
VAS pain score at 1, 2, 6, 12,
24 h after surgery
Side effects (0-24 h): Nausea
and vomiting, sedation,
respiratory depression,
pruritus, use of antiemetics
Ohnesorge
[37] 2009
27 26 L/U/L/LU ASA I-III, elective
breast surgery
1 g i.v. paracetamol
1 g i.v. metamizol
20 min before end of
surgery and 4, 10, 16 h after
surgery
NRS (11-point) pain scale,
vigilance, nausea 0.5, 1, 2, 4,
6, 10, 24 h after surgery
Need for rescue morphine
Total morphine
consumption 24 h
Patient satisfaction,
cognitive function
Time to ﬁrst ambulation
Platzer [39]
2011
40 39 L/L/H/L/L ASA I-II, children age
3–13 years,
tonsillectomy,
adenoidectomy or
adenotonsillectomy
15 mg kg1 paracetamol
2 mg kg1 ketoprofen
5-point smiley scale at 0.5, 1
2, 3, 4 h after PACU arrival
Morphine consumption
Time to rescue morphine
Vomiting
Additional
2 mg kg1
ketoprofen
additional
propofol
Salihoglu
[42] 2009
20 20 L/L/L/L/L ASA I-II, laparoscopic
cholecystectomy
1 g i.v. paracetamol after
intubation
Verbal (4-point) and VAS
(11-point) pain scales at 5,
10, 15, 30, 60 min after
recovery
Time of ﬁrst rescue
morphine in PACU
Total morphine
consumption
Duration of stay in PACU
Awakening time, extubation
time
Nausea, vomiting
Sinatra [43]
2005
49 52 L/L/L/L/L ASA I-III, orthopedic
surgery
1 g i.v. acetaminophen on
morning of postsurgery day
1 and for every 6 h for 24 h
2 g i.v. propacetamol
VAS (0-100) pain scale,
verbal pain scale (4-point),
pain relief (5-point) at 0.25,
0.5, 0.75, 1, 2, 3, 4, 5, 6, 18,
20, 24 h after ﬁrst dose
Time to rescue medication
Total morphine
consumption
Patients satisfaction over
Patient-
controlled
morphine
analgesia
(continued on next page)
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Table 1 (continued)
Study (ﬁrst
author) Year
Number of
patients
acetaminophen
Number
of
patients
placebo
Risk of bias
assessmenta
Patients/type of
surgery
Intervention Outcomes Comments
24 h
TOTPAR6, SPID6, SPRID 6
Side effects: nausea,
vomiting, constipation,
abdominal enlargement,
injection site pain/reaction,
fever, anemia, pruritus,
coughing
Topal [45]
2009
20 20 U/U/H/U/L ASA I-II, inguinal
hernia repair
1 g paracetamol before end
of surgery and for every 6 h
for 24 h
VAS (11-point) pain scale
and sedation at 0.25, 0.5, 1,
2, 4, 6, 8, 12, 16, 24 h
postsurgery
Total morphine
consumption
Nausea, vomiting,
antiemetic use, respiratory
depression, pruritus
Additional
0.05 mg kg1
morphine at end
of surgery and
patient
controlled
morphine
analgesia
Toygar [46]
2008
60 30 U/H/H/H/U Lumbar diskectomy 1 g paracetamol 15 min
before induction of
anesthesia
1 g paracetamol 15 min
before end of surgery
VAS pain scale 0, 1, 2, 3, 6,
12, 24 h
Time to rescue morphine
Total morphine
consumption
Side effects: Nausea,
vomiting, urinary retention
Uvarov [48]
2008
25 24 L/U/H/H/L Thoracotomy 1 g i.v. paracetamol before
end of surgery and every 6 h
for 24 h
Rectal paracetamol
VAS pain scale 3,6,12,18,24 h
total consumption
ropivacaine/fentanyl
Side effects: Nausea or
vomiting, skin itching,
urinary retention
Additional
epidural patient
controlled
analgesia with
ropivacaine and
fentanyl and
30 mg i.m.
ketorolac
Viscusi [49]
2008
35 34 L/L/L/L/L Total hip arthroplasty On postsurgery day 1: 1 g
paracetamol vs. placebo.
Nausea: i.v. acetaminophen
2/35
Placebo 0/34
Vomiting: i.v.
acetaminophen 13/35
Placebo 7/34
BMS study data
per study report
received from
Cadence
Pharmaceutical
Wininger
[52] 2010
134 110 L/L/L/L/L Abdominal
laparoscopic surgery
Start of medication at
postsurgery day 1: 650 mg
acetaminophen every 4 h for
24 h
1000 mg acetaminophen
every 6 h for 24 h
Pain intensity (4-point), VAS
(100 mm) pain scale, Pain
relief(5-point) at 0, 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 14, 16,
18, 20, 22, 24 h on
postsurgery day 1
Amount of and time to ﬁrst
morphine or
hydromorphone
Patient satisfaction (4-point)
after 24 h
TOTPAR at 4, 6, 24 h, SPID at
4, 6, 24 h
Side effects: Nausea,
vomiting, constipation,
diarrhea, ﬂatulence,
infusion-site pain, pyrexia,
incision-site pain, back pain,
headache, psychiatric
disorders, insomnia,
dyspnea
U, unclear; L, low; H, high; ASA, American Society of Anesthesiology; i.v., intravenous; VAS, visual analogue scale; PAR, pain relief; SPID, summed pain intensity difference;
TOTPAR, total pain relief; MAXPID, maximum pain intensity difference; MAXPAR, maximum pain relief; PID, pain intensity difference; NRS, numerical rating scale; PONV,
postoperative nausea and vomiting; PCA, patient-controlled analgesia; PACU, postanesthesia care unit; SPRID, sum of pain relief and pain intensity difference; BMS, Bristol-
Myers Squibb.
a The categories in Risk of Bias Assessment are: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome
assessment, and incomplete outcome data.
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Further sensitivity analyses revealed that prophylactically
administered i.v. acetaminophen reduced nausea and vomitingirrespective of whether it was started before surgery, intraopera-
tively, or immediately after surgery (Fig. 4, Table 2). However, a
single prophylactic dose of i.v. acetaminophen was associated with
less nausea (0.50, 0.38–0.66) than if the dose was repeated (0.72,
Study or Subgroup
Arici 2009 BS
Arici 2009 IS
Arslan 2011 IS
Atef 2008 IR
Brodner 2011 IR
Cakan 2008 IR
Candiotti 2008 RR
Cattabriga 2007 IR
Cok 2011 IS
Fadly 2006 IS
Gimbel 2008 RR
Gokten 2011 PR
Grundmann 2006 IS
Hong2 2010 BR
Jokela 2010 BR
Kilicaslan 2010 IR
Lee 2010 IS
Memis 2010 PR
Minkowitz 2008 RR
Moon 2011 BS
Ohnesorge 2009 IR
Salihoglu 2009 BS
Sinatra 2011 RR
Topal 2009 IR
Toygar 2008 BS
Toygar 2008 IS
Uvarov 2008 IR
Viscusi 2008 RR
Wininger a 2010 RR
Wininger b 2010 RR
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.08; Chi² = 46.93, df = 29 (P = 0.02); I² = 38%
Test for overall effect: Z = 3.21 (P = 0.001)
Events
3
3
9
7
15
12
96
3
6
0
4
1
1
14
8
11
2
1
9
13
9
2
13
9
4
3
1
2
16
4
281
Total
28
27
20
38
49
20
166
56
41
10
30
20
20
63
40
25
20
20
23
36
27
20
49
20
30
30
25
35
91
43
1122
Events
9
9
18
10
21
17
88
1
15
3
7
6
1
27
12
12
1
8
9
21
7
5
7
10
7
7
1
0
3
9
351
Total
27
27
20
38
49
20
165
57
45
10
31
20
20
61
40
25
20
20
21
35
26
20
52
20
30
30
24
34
43
67
1097
Weight
2.2%
2.2%
6.6%
3.6%
6.3%
7.9%
10.6%
0.7%
3.6%
0.4%
2.4%
0.9%
0.5%
6.2%
4.1%
5.5%
0.7%
0.9%
4.6%
6.5%
3.7%
1.4%
3.7%
5.1%
2.4%
2.0%
0.5%
0.4%
2.2%
2.4%
100.0%
M-H, Random, 95% CI
0.32 [0.10, 1.06]
0.33 [0.10, 1.10]
0.50 [0.30, 0.83]
0.70 [0.30, 1.65]
0.71 [0.42, 1.22]
0.71 [0.47, 1.06]
1.08 [0.89, 1.32]
3.05 [0.33, 28.48]
0.44 [0.19, 1.02]
0.14 [0.01, 2.45]
0.59 [0.19, 1.81]
0.17 [0.02, 1.26]
1.00 [0.07, 14.90]
0.50 [0.29, 0.86]
0.67 [0.31, 1.45]
0.92 [0.50, 1.67]
2.00 [0.20, 20.33]
0.13 [0.02, 0.91]
0.91 [0.45, 1.86]
0.60 [0.36, 1.00]
1.24 [0.54, 2.83]
0.40 [0.09, 1.83]
1.97 [0.86, 4.53]
0.90 [0.47, 1.73]
0.57 [0.19, 1.75]
0.43 [0.12, 1.50]
0.96 [0.06, 14.50]
4.86 [0.24, 97.69]
2.52 [0.78, 8.19]
0.69 [0.23, 2.11]
0.73 [0.60, 0.88]
Acetaminophen Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favors acetaminophen Favors placebo
Fig. 2. Effect of intravenous acetaminophen on postoperative nausea. CI, conﬁdence interval; BS, before surgery, single dose; IS, during or immediately after surgery, single
dose; IR, during or immediately after surgery, repeated dose; RR, rescue medication, repeated dose; PR, postoperative, repeated dose; BR, before surgery, repeated dose.
C.C. Apfel et al. / PAIN

154 (2013) 677–689 6830.58–0.89, P-value for sub-group differences 0.04, Fig. 5). Results
for vomiting were similar, with P-value for sub-group differences
of 0.13 (Table 2). Reduction of postoperative opioids (average
reductions were about 9 mg of morphine equivalents) did not
contribute to the antiemetic effect of prophylactic i.v. acetamino-
phen, with an odds ratio of 0.89 (0.64–1.22) for 10 mg of morphine
equivalents (Fig. 6, P = 0.45). However, reduction in postoperative
pain (average reduction was about 0.9 points on a 0–10 scale)
was associated with a signiﬁcant reduction in postoperative nau-
sea, with an odds ratio of 0.66 (0.47–0.93) per 1 point (Fig. 7,
P = 0.02). Egger’s regression tests did not reveal any evidence of
publication bias for any of the outcomes studied (P > 0.05 for all
outcomes, Table 2).
4. Discussion
We found that prophylactic i.v. acetaminophen reduced PONV.
Interestingly, timing of treatment markedly inﬂuenced the treat-
ment effect: i.v. acetaminophen was most effective against PONV
when given before surgery and intraoperatively, but not when
treatment was initiated after onset of pain. Further, when i.v. acet-
aminophen was given prophylactically, the reduction of PONV cor-
related with the reported reduction of pain, but not postoperative
opioid consumption.4.1. Critique against previous systematic reviews
At the time thismanuscriptwasbeingwritten, several systematic
and narrative reviews have been published, all noting that i.v.
acetaminophen does not reduce PONV [24,30,31,40,41,47,53]. This
includes a Cochrane review that identiﬁed only 4 papers, even
though at the time of the last search, May 2010, 19 of the 30 papers
that we identiﬁed had already been published [47]. It is disconcert-
ing that so many studies had not been identiﬁed in the Cochrane
review, despite the explicit reporting and application of fairly com-
plex search strategies. Further research intowhy this happens is cer-
tainly indicated if we want to improve the reliability of systematic
reviews. Therefore, we investigated the effect of i.v. acetaminophen
as ourmain outcome and included the new evidence in our analysis.
4.2. Timing of i.v. administration
Cumulative results showed a high degree of heterogeneity,
which prompted further sensitivity analyses. We analyzed the
results according to the source of funding. To our surprise,
industry-sponsored trials did not show a reduction of PONV, while
independent, investigator-initiated trials showed a clear reduction
in PONV. We thus reviewed the study designs and found that i.v.
acetaminophen was given for rescue treatment only in industry-
Study or Subgroup
Arici 2009 BS
Arici 2009 IS
Arslan 2011 IS
Brodner 2011 IR
Cakan 2008 IR
Candiotti 2008 RR
Cok 2011 IS
Emir 2010 IR
Gimbel 2008 RR
Hong1 2010 IR
Hong2 2010 BR
Jokela 2010 BR
Kilicaslan 2010 IR
Minkowitz 2008 RR
Ohnesorge 2009 IR
Platzer 2011 IS
Salihoglu 2009 BS
Sinatra 2011 RR
Topal 2009 IR
Toygar 2008 BS
Toygar 2008 IS
Viscusi 2008 RR
Wininger a 2010 RR
Wininger b 2010 RR
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.28; Chi² = 43.35, df = 23 (P = 0.006); I² = 47%
Test for overall effect: Z = 2.67 (P = 0.008)
Events
2
3
5
9
7
37
3
0
1
5
4
2
3
7
1
1
1
6
3
0
1
13
7
4
125
Total
28
27
20
49
20
166
41
30
30
31
63
40
25
23
27
40
20
49
20
30
30
35
91
42
977
Events
9
9
14
12
14
28
11
2
2
18
13
4
4
7
1
1
3
3
4
5
5
7
0
2
178
Total
27
27
20
49
20
165
45
30
31
32
61
40
25
21
26
39
20
52
20
30
30
34
43
67
954
Weight
3.7%
4.7%
6.8%
7.1%
7.8%
9.3%
4.7%
1.2%
1.8%
6.5%
5.3%
3.1%
3.9%
6.5%
1.4%
1.4%
2.0%
4.1%
4.0%
1.3%
2.2%
6.9%
1.3%
3.1%
100.0%
M-H, Random, 95% CI
0.21 [0.05, 0.90]
0.33 [0.10, 1.10]
0.36 [0.16, 0.80]
0.75 [0.35, 1.62]
0.50 [0.26, 0.97]
1.31 [0.84, 2.04]
0.30 [0.09, 1.00]
0.20 [0.01, 4.00]
0.52 [0.05, 5.40]
0.29 [0.12, 0.68]
0.30 [0.10, 0.86]
0.50 [0.10, 2.58]
0.75 [0.19, 3.01]
0.91 [0.38, 2.17]
0.96 [0.06, 14.60]
0.97 [0.06, 15.05]
0.33 [0.04, 2.94]
2.12 [0.56, 8.02]
0.75 [0.19, 2.93]
0.09 [0.01, 1.57]
0.20 [0.02, 1.61]
1.80 [0.82, 3.97]
7.17 [0.42, 122.80]
3.19 [0.61, 16.66]
0.63 [0.45, 0.88]
Acetaminophen Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favors acetaminiphen Favors placebo
Fig. 3. Effect of intravenous acetaminophen on postoperative vomiting. CI, conﬁdence interval; BS, before surgery, single dose; IS, during or immediately after surgery, single
dose; IR, during or immediately after surgery, repeated dose; RR, rescue medication, repeated dose; PR, postoperative, repeated dose; BR, before surgery, repeated dose.
Table 2
Efﬁcacy of i.v. acetaminophen to reduce nausea and vomiting.
Comparison Acetaminophen Control Risk ratio 95% CI P-value of effect P-value heterogeneity P-value Egger’s test
Nausea 281/1122 351/1097 0.73 0.60–0.88 0.001 0.02 0.07
Industry sponsored trials/as rescue 144/437 123/413 1.12 0.85–1.48 0.42 0.32 0.60
Investigator initiated trials/prophylactic 137/685 228/684 0.63 0.54–0.75 < 0.001 0.60 0.36
Before surgery 44/217 81/213 0.54 0.40–0.74 <0.001 0.92 0.31
During or immediately after surgery 93/468 147/471 0.67 0.55–0.83 <0.001 0.39 0.50
Prophylactic single dose 46/282 96/284 0.50 0.38–0.66 <0.001 0.94 0.64
Prophylactic repeated doses 91/403 132/400 0.72 0.58–0.89 0.002 0.41 0.74
Vomiting 125/977 178/954 0.63 0.45–0.88 0.008 0.006 0.20
Industry-sponsored trials/as rescue 75/436 49/413 1.41 1.02–1.96 0.04 0.57 0.40
Investigator-initiated trials/prophylactic 50/541 129/541 0.42 0.31–0.56 <0.001 0.90 0.40
Before surgery 9/181 34/178 0.29 0.14–0.57 <0.001 0.87 0.55
During or immediately after surgery 41/360 95/363 0.46 0.33–0.63 <0.001 0.84 0.93
Prophylactic single dose 16/236 57/238 0.31 0.19–0.51 <0.001 0.96 0.52
Prophylactic repeated doses 34/305 72/303 0.49 0.35–0.70 <0.001 0.77 0.96
i.v., intravenous; CI, conﬁdence interval.
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154 (2013) 677–689sponsored trials, and i.v. acetaminophenwas given prophylactically
in investigator-initiated trials. Furthermore, heterogeneity van-
ished when the studies were stratiﬁed for timing. We classiﬁed
the studies into 3 main subgroups: studies in which i.v. acetamino-
phen was administered a) before surgery, b) during or shortly after
the end of surgery, and c) after recovery from anesthesia at onset of
pain. Intravenous acetaminophen was shown to be effective for
both nausea and vomiting only when administered prophylacti-
cally. In contrast, in industry-sponsored trials in which i.v. acetami-
nophenwas given after the onset of pain (often only initiated on the
ﬁrst postoperative day), it did not reduce PONV. Hence, the differ-
ences between investigator-initiated and industry-sponsored trials
can be attributed to the differences in timing of treatment.4.3. Prophylactic single versus repeated dosage
As a secondary sensitivity analysis, we separated studies with
prophylactically applied i.v. acetaminophen into those where a sin-
gle dose was given, compared to repeated dosage. While the reduc-
tion of vomiting was not statistically signiﬁcantly different
between single and repeated doses, nausea was more reduced by
the single dose (risk ratio 0.31) compared to repeated doses (risk
ratio 0.49, P-value for single vs. repeated comparison = 0.04). These
data suggest that i.v. acetaminophen reduces PONV at least as well
as established antiemetics, which generally have a risk ratio of 0.60
to 0.80 [1,12]. However, it would be surprising if a single dose of
i.v. acetaminophen would be more than twice as effective as con-
Study or Subgroup
1.13.1 Before surgery
Salihoglu 2009 BS
Arici 2009 BS
Toygar 2008 BS
Jokela 2010 BR
Hong2 2010 BR
Moon 2011 BS
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.42, df = 5 (P = 0.92); I² = 0%
Test for overall effect: Z = 3.93 (P < 0.0001)
1.13.2 Intraoperatively
Uvarov 2008 IR
Grundmann 2006 IS
Lee 2010 IS
Cattabriga 2007 IR
Toygar 2008 IS
Arici 2009 IS
Cok 2011 IS
Ohnesorge 2009 IR
Topal 2009 IR
Kilicaslan 2010 IR
Brodner 2011 IR
Arslan 2011 IS
Cakan 2008 IR
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 10.68, df = 12 (P = 0.56); I² = 0%
Test for overall effect: Z = 3.36 (P = 0.0008)
1.13.3 Immediately after surgery
Fadly 2006 IS
Gokten 2011 PR
Memis 2010 PR
Atef 2008 IR
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.40; Chi² = 4.50, df = 3 (P = 0.21); I² = 33%
Test for overall effect: Z = 2.18 (P = 0.03)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 19.80, df = 22 (P = 0.60); I² = 0%
Test for overall effect: Z = 5.40 (P < 0.00001)
Test for subgroup differences: Chi² = 3.70, df = 2 (P = 0.16), I² = 46.0%
Events
2
3
4
8
14
13
44
1
1
2
3
3
3
6
9
9
11
15
9
12
84
0
1
1
7
9
137
Total
20
28
30
40
63
36
217
25
20
20
56
30
27
41
27
20
25
49
20
20
380
10
20
20
38
88
685
Events
5
9
7
12
27
21
81
1
1
1
1
7
9
15
7
10
12
21
18
17
120
3
6
8
10
27
228
Total
20
27
30
40
61
35
213
24
20
20
57
30
27
45
26
20
25
49
20
20
383
10
20
20
38
88
684
Weight
1.2%
1.9%
2.2%
4.5%
9.4%
10.5%
29.7%
0.4%
0.4%
0.5%
0.6%
1.7%
1.9%
3.8%
4.0%
6.4%
7.6%
9.7%
10.7%
17.0%
64.8%
0.3%
0.7%
0.7%
3.8%
5.5%
100.0%
M-H, Random, 95% CI
0.40 [0.09, 1.83]
0.32 [0.10, 1.06]
0.57 [0.19, 1.75]
0.67 [0.31, 1.45]
0.50 [0.29, 0.86]
0.60 [0.36, 1.00]
0.54 [0.40, 0.74]
0.96 [0.06, 14.50]
1.00 [0.07, 14.90]
2.00 [0.20, 20.33]
3.05 [0.33, 28.48]
0.43 [0.12, 1.50]
0.33 [0.10, 1.10]
0.44 [0.19, 1.02]
1.24 [0.54, 2.83]
0.90 [0.47, 1.73]
0.92 [0.50, 1.67]
0.71 [0.42, 1.22]
0.50 [0.30, 0.83]
0.71 [0.47, 1.06]
0.70 [0.57, 0.86]
0.14 [0.01, 2.45]
0.17 [0.02, 1.26]
0.13 [0.02, 0.91]
0.70 [0.30, 1.65]
0.31 [0.11, 0.89]
0.63 [0.54, 0.75]
Acetaminophen Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favors acetaminophen Favors placebo
Fig. 4. Effect of prophylactic intravenous acetaminophen on postoperative nausea according to timing of administration. CI, conﬁdence interval; BS, before surgery, single
dose; BR, before surgery, repeated dose; IR, during or immediately after surgery, repeated dose; IS, during or immediately after surgery, single dose; PR, postoperative,
repeated dose.
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a single dose of prophylactic i.v. acetaminophen is at least as effec-
tive as repeated doses or as antiemetics.
4.4. Potential mechanisms
To elucidate the mechanisms of PONV reduction by i.v. acetami-
nophen, we performed meta-regressions of the effects of opioid
consumption and pain intensity on postoperative nausea. It is gen-
erally accepted that the antiemetic effect of NSAIDs is mediated by
a dose-dependent reduction in opioid consumption; thus, it seems
plausible that i.v. acetaminophen might also reduce PONV by
reducing postoperative opioid requirements. In contrast to ourexpectations, reduction of PONV was not signiﬁcantly associated
with reduction of morphine equivalents; however, it was associ-
ated with a reduction in pain intensity. Pain itself is commonly be-
lieved to be a risk factor for PONV among clinicians, and this may
be the ﬁrst report to support this notion. Another potential mech-
anism could be a direct antiemetic effect of acetaminophen. In fact,
acetaminophen is metabolized in the brain into AM404, a metabo-
lite that is able to inhibit the reuptake of anandamide, a known
cannabinoid CB1 and CB2 receptor agonist. It has been shown that
decreased anandamide levels are associated with an increased rate
of nausea and vomiting in humans [14]. Therefore, it is possible
that acetaminophen simply has a direct effect on PONV by increas-
ing anandamide levels.
Study or Subgroup
1.15.1 Single Dosage
Arici 2009 BS
Arici 2009 IS
Arslan 2011 IS
Cok 2011 IS
Fadly 2006 IS
Grundmann 2006 IS
Lee 2010 IS
Moon 2011 BS
Salihoglu 2009 BS
Toygar 2008 BS
Toygar 2008 IS
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 4.20, df = 10 (P = 0.94); I² = 0%
Test for overall effect: Z = 4.84 (P < 0.00001)
1.15.2 Repeated Dosage
Atef 2008 IR
Brodner 2011 IR
Cakan 2008 IR
Cattabriga 2007 IR
Gokten 2011 PR
Hong2 2010 BR
Jokela 2010 BR
Kilicaslan 2010 IR
Memis 2010 PR
Ohnesorge 2009 IR
Topal 2009 IR
Uvarov 2008 IR
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 11.35, df = 11 (P = 0.41); I² = 3%
Test for overall effect: Z = 3.04 (P = 0.002)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 19.80, df = 22 (P = 0.60); I² = 0%
Test for overall effect: Z = 5.40 (P < 0.00001)
Test for subgroup differences: Chi² = 4.06, df = 1 (P = 0.04), I² = 75.4%
Events
3
3
9
6
0
1
2
13
2
4
3
46
7
15
12
3
1
14
8
11
1
9
9
1
91
137
Total
28
27
20
41
10
20
20
36
20
30
30
282
38
49
20
56
20
63
40
25
20
27
20
25
403
685
Events
9
9
18
15
3
1
1
21
5
7
7
96
10
21
17
1
6
27
12
12
8
7
10
1
132
228
Total
27
27
20
45
10
20
20
35
20
30
30
284
38
49
20
57
20
61
40
25
20
26
20
24
400
684
Weight
1.9%
1.9%
10.7%
3.8%
0.3%
0.4%
0.5%
10.5%
1.2%
2.2%
1.7%
35.3%
3.8%
9.7%
17.0%
0.6%
0.7%
9.4%
4.5%
7.6%
0.7%
4.0%
6.4%
0.4%
64.7%
100.0%
M-H, Random, 95% CI
0.32 [0.10, 1.06]
0.33 [0.10, 1.10]
0.50 [0.30, 0.83]
0.44 [0.19, 1.02]
0.14 [0.01, 2.45]
1.00 [0.07, 14.90]
2.00 [0.20, 20.33]
0.60 [0.36, 1.00]
0.40 [0.09, 1.83]
0.57 [0.19, 1.75]
0.43 [0.12, 1.50]
0.50 [0.38, 0.66]
0.70 [0.30, 1.65]
0.71 [0.42, 1.22]
0.71 [0.47, 1.06]
3.05 [0.33, 28.48]
0.17 [0.02, 1.26]
0.50 [0.29, 0.86]
0.67 [0.31, 1.45]
0.92 [0.50, 1.67]
0.13 [0.02, 0.91]
1.24 [0.54, 2.83]
0.90 [0.47, 1.73]
0.96 [0.06, 14.50]
0.72 [0.58, 0.89]
0.63 [0.54, 0.75]
Acetaminophen Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favors acetaminophen Favors placebo
Fig. 5. Effect of single vs repeated dosing of intravenous acetaminophen on postoperative nausea. CI, conﬁdence interval; BS, before surgery, single dose; IS, during or
immediately after surgery, single dose; IR, during or immediately after surgery, repeated dose; RR, rescue medication, repeated dose; PR, postoperative, repeated dose; BR,
before surgery, repeated dose.
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The validity of any systematic review and meta-analysis de-
pends on the validity and quality of the published material, the
methodological approach, and appropriate critical appraisal of
the study results. We have thus analyzed the data regarding the
risk of bias of various components and did not ﬁnd signiﬁcant dif-
ferences. In particular, neither funnel plots nor Egger’s regression
tests suggested any evidence for a publication bias. However,
investigator-initiated studies were generally small and of similar
size, which limits the chance to detect publication bias. Thus,
although the effectiveness of prophylactically administered
i.v. acetaminophen was consistent (without any signiﬁcant in-
between-study heterogeneity), a large, well-designed random-
ized-controlled trial would be warranted to conﬁrm these
ﬁndings.4.6. Conclusion
In summary, this systematic review and meta-analysis demon-
strated that prophylactic i.v. acetaminophen reduces postoperative
nausea and vomiting with an effect size that compares well with
data known from other antiemetics. The results from our meta-
regression suggest that the antiemetic effect of i.v. acetaminophen
is not mediated through the reduction of postoperative opioid con-
sumption, but through direct mechanisms or through the reduc-
tion of postsurgical pain.
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Fig. 7. Meta-regression of average pain intensity reduction on log odds ratio for nausea. Average Pain Intensity refers to a scale from 0 to 10.
Fig. 6. Meta-regression of morphine reduction on log odds ratio for nausea Morph Reduction (mg) refers to a postoperative opioid reduction in 1-mg morphine equivalents as
a result of intravenous acetaminophen vs control (for further details see Methods section).
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